Florfenicol + Mometasone Furoate + Terbinafine Hcl

Verify with FDA CVM →

19 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

FlorfenicolMometasone FuroateTerbinafine Hcl

Administration Routes

UnknownAuricular (Otic)Topical

Species Affected

Dog 16
Cat 3

Most Affected Breeds

Retriever - Golden 3
Maltese 2
Retriever - Labrador 2
Domestic Shorthair 1
Ragdoll 1
Chihuahua 1
Cat (other) 1
Pekingese 1
Pug 1
Poodle - Standard 1

Most Reported Reactions

Vomiting 5
Vestibular disorder NOS 4
Ataxia 4
Lack of efficacy - NOS 4
Lack of efficacy (bacteria) - NOS 4
Otorrhoea 4
Unable to stand 3
Abnormal pupil light reflex 3
Other abnormal test result NOS 3
Abnormal cytology 3
Decreased appetite 3
Behavioural disorder NOS 2

Outcome Breakdown

Outcome Unknown
7 (36.8%)
Recovered/Normal
6 (31.6%)
Ongoing
6 (31.6%)

Data Summary

Metric Value
Total adverse event reports 19
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 15
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Florfenicol + Mometasone Furoate + Terbinafine Hcl Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 19 adverse event reports referencing Florfenicol + Mometasone Furoate + Terbinafine Hcl, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Florfenicol, Mometasone Furoate, Terbinafine Hcl. Reported administration routes include Unknown, Auricular (Otic), Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Florfenicol + Mometasone Furoate + Terbinafine Hcl reports are Dog (16 reports), Cat (3 reports), with Dog accounting for the largest share. Within those species, Retriever - Golden (3), Maltese (2), Retriever - Labrador (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Florfenicol + Mometasone Furoate + Terbinafine Hcl are Vomiting (5), Vestibular disorder NOS (4), Ataxia (4), Lack of efficacy - NOS (4). Of the 19 reports with a coded outcome, Outcome Unknown is the leading category at 36.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Florfenicol + Mometasone Furoate + Terbinafine Hcl.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial